Company
Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Scribe Therapeutics

Main focus: Development of CasX for therapeutic use in genetic diseases

Company stage: Pre-clinical

Diseases: Amyotrophic lateral sclerosis (ALS), otherwise undisclosed

Genome editing tool: CRISPR-CasX

Funding stage: Private

Location: San Francisco Bay Area, California, United States

Website: https://www.scribetx.com/

Partners: Biogen

Scribe Therapeutics develops novel Cas variants, in particular the CasX enzyme, for the treatment of genetic diseases. The company has yet to disclose its pre-clinical pipeline. However, it has unveiled a collaboration with Biogen focusing on ALS.

Tags

HashtagScribe Therapeutics

Company: Scribe Therapeutics
close
Search CRISPR Medicine